New options for uveitis treatment

International Journal of Ophthalmology

Volumn 6, Issue 5, 2013, Pages 702-707

  He, Yu ^a,b   Jia, Song Bai ^b   Zhang, Wei ^a   Shi, Jing Ming ^b  

^a Center Hospital of Fuling   (China)

^b CENTRAL SOUTH UNIVERSITY   (China)

Author keywords

Biologic agents; Gene therapy; Intravitreal implants; RNA interference; Uveitis

Indexed keywords

EID: 84894588451     PISSN: 22223959     EISSN: 22274898     Source Type: Journal    
DOI: 10.3980/j.issn.2222-3959.2013.05.29     Document Type: Article

References (55)

1. Durrani OM, Meads CA, Murray PI. Uveitis: A potentially blinding disease. Ophthalmologica. 2004;218(4):223-236.
2. Kaemaz RO, Kempen JH, Newcomb C, Daniel E, Gangaputra S, Nussenblatt RB, Rosenbaum JT, Suhler EB, Thorne JE, Jabs DA, Levy-Clarke GA, Foster CS. Cyclosporine for ocular inflammatory diseases. Ophthalmology. 2010;117(3):576-584.
3. Pasadhika S, Kempen JH, Newcomb CW, Liesegang TL, Pujari SS, Rosenbaum JT, Thorne JE, Foster CS, Jabs DA, Levy-Clarke GA, Nussenblatt RB, Suhler EB. Azathioprine for ocular inflammatory diseases. Am J Ophthalmol. 2009;148(4):500-509.
4. Daniel E, Thorne JE, Newcomb CW, Pujari SS, Kaemaz RO, Levy-Clarke GA, Nussenblatt RB, Rosenbaum JT, Suhler EB, Foster CS, Jabs DA, Kempen JH. Mycophenolate mofetil for ocular inflammation. Am J Ophthalmol. 2010;149(3):423-432.
5. De Smet MD, Taylor SR, Bodaghi B, Miserocchi E, Murray PI, Pleyer U, Zierhut M, Barisani-Asenbauer T, Le Hoang P, Lightman S. Understanding uveitis: the impact of research on visual outcomes. Prog Retin Eye Res. 2011;30(6):452-470.
6. Baranano DE, Kim SJ, Edelhauser HF, Durairaj C, Kompella UB, Handa JT. Efficacy and pharmacokinetics of intravitreal non-steroidal anti-inflammatory drugs for intraocular inflammation. Br J Ophthalmol. 2009;93(10):1387-1390.
7. Soheilian M, Karimi S, Ramezani A, Peyman GA. Pilot study of intravitreal injection of diclofenac for treatment of macular edema of various etiologies. Retina. 2010;30(3):509-515.
8. Kim SJ, Doherty TJ, Cherney EF. Intravitreal ketorolac for chronic uveitis and macular edema: A pilot study. Arch Ophthalmol. 2012;130(4):456-460.
9. Hardwig PW, Pulido JS, Erie JC, Baratz KH, Buettner H. Intraocular methotrexate in ocular diseases other than primary central nervous system lymphoma. Am J Ophthalmol. 2006;142(5):883-885.
10. Taylor SR, Habot-Wilner Z, Pacheco P, Lightman SL. Intraocular methotrexate in the treatment of uveitis and uveitic cystoid macular edema. Ophthalmology. 2009;116(4):797-801.
11. Bae JH, Lee SC. Effect of intravitreal methotrexate and aqueou s humor cytokine levels in refractory retinal vasculitis in behcet disease. Retina. 2012;32(7):1395-1402.
12. De Smet MD. Corticosteroid intravitreal implants. Dev Ophthalmol. 2012;51:122-133.
13. Robinson MR, Whitcup SM. Pharmacologic and clinical profile of dexamethasone intravitreal implant. Expert Rev Clin pharmacol. 2012;5(6):629-647.
14. Miserocchi E, Modorati G, Pastore M, Bandello F. Dexamethasone intravitreal implant: An effective adjunctive treatment for recalcitrant noninfectious uveitis. Ophthalmologica. 2012;228(4):229-233.
15. Taylor SR, Tomkins-Netzer O, Joshi L, Morarji J, McLoone E, Lightman S. Dexamethasone implant in pediatric uveitis. Ophthalmology. 2012;119(11):2412- 2412.
16. Patel CC, Mandava N, Oliver SC, Braverman R, Quiroz-Mercado H, Olson JL. Treatment of intractable posterior uveitis in pediatric patients with the fluocinolone acetonide intravitreal implant (retisert) Retina. 2012;32(3):537-542.
17. Allen R C, Suhler EB, Flaxel CJ, Chen Z, Choi D. Long-term follow-up of patients treated with multiple fluocinolone acetonide implants for noninfectious uveitis. J Ophthalmic Inflamm Infect. 2012;2(4):177-182.
18. Arcinue CA, Cerón OM, Foster CS. A comparison between the fluocinolone acetonide (retisert) and dexamethasone (ozurdex) intravitreal implants in uveitis. J Ocul Pharmacol Ther. 2013;29(5):501-507.
19. Gomes Bittencourt M, Sepah Y J, Do DV, Agbedia O, Akhtar A, Liu H, Akhlap A, Annam R, Ibrahim M, Nguyen QD. New treatment options for noninfectious uveitis. Dev Ophthalmol. 2012;51:134-161.
20. Erckens RJ, Mostard RL, Wijnen PA, Schouten JS, Drent M. Adalimumab successful in sarcoidosis patients with refractory chronic non-infectious uveitis. Graefes Arch Clin Exp Ophthalmol. 2012;250(5):713-720.
21. Kotaniemi K, Säilä H, Kautiainen H. Long-term efficacy of adalimumab in the treatment of uveitis associated with juvenile idiopathic arthritis. Clin Ophthalmol. 2011;5:1425-1429.
22. Neri P, Zucchi M, Allegri P, Lettieri M, Mariotti C, Giovannini A. Adalimumab (humira™): a promising monoclonal anti-tumor necrosis factor alpha in ophthalmology. Int Ophthalmol. 2011;31(2):165-173.
23. Olivieri I, Leccese P, D'angelo S, Padula A, Nigro A, Palazzi C, Coniglio G, Latanza L. Efficacy of adalimumab in patients with behçet's disease unsuccessfully treated with infliximab. Clin Exp Rheumatol. 2011;29(4):54-57.
24. Díaz-Llopis M, Salom D, Garcia-de-Vicuña C, Cordero-Coma M, Ortega G, Ortego N, Suarez-de-Figueroa M, Rio-Pardo MJ, Fernandez-Cid C, Fonollosa A, Blanco R, Garcia-Aparicio A M, Benitez-Del-Castillo JM, Olea JL, Arevalo JF. Treatment of refractory uveitis with adalimumab: a prospective multicenter study of 131 patients. Ophthalmology. 2012;119(8):1575-1581.
25. Androudi S, Tsironi E, Kalogeropoulos C, Theodoridou A, Brazitikos P. Intravitreal adalimumab for refractory uveitisrelated macular edema. Ophthalmology. 2010;117(8):1612-1616.
26. Handa T, Tsunekawa H, Yoneda M, Watanabe D, Mukai T, Yamamura M, Iwaki M, Zako M. Longterm remission of ocular and extraocular manifestations in behçet's disease using infliximab. Clin Exp Rheumatol. 2011;29(67):58-63.
27. Capella MJ, Foster CS. Long-term efficacy and safety of infliximab in the treatment of behçet's disease. Ocul Immunol Inflamm. 2012;20(3):198-202.
28. Iwata S, Saito K, Yamaoka K, Tsujimura S, Nawata M, Hanami K, Tanaka Y. Efficacy of combination therapy of anti-TNF-a antibody infliximab and methotrexate in refractory entero-behçet's disease. Mod Rheumatol. 2011;21(2):184-191.
29. Modorati G, Miserocchi E. Intravitreal injection therapy in the treatment of noninfectious uveitis. Dev Ophthalmol. 2012;51:110-121.
30. Farvardin M, Afarid M, Shahrzad S. Long-term effects of intravitreal infliximab for treatment of sight-threatening chronic noninfectious uveitis. J Ocul Pharmacol Ther. 2012;28(6):628-631.
31. Wu L, Arevalo J, Hernandez-Bogantes E, Roca J. Intravitreal infliximab for refractory pseudophakic cystoid macular edema: Results of the pan-american collaborative retina study group. Int Ophthalmol. 2012;32(3):235-243.
32. Giganit M, Beer PM, Lemanski N, Hartman C, Schartman J, Falk N. Adverse events after intravitreal infliximab (remicade) Retina. 2010;30(1):71-80.
33. Pulido JS, Pulido JE, Michet CJ, Vile RG. More questions than answers: A call for a moratorium on the use of intravitreal infliximab outside of a well-designed trial. Retina. 2010;30(1):1-5.
34. Angeles-han S, Flynn T, Lehman T. Abatacept for refractory juvenile idiopathic arthritis-associated uveitis-a case report. J Rheumatol. 2008;35(9):1897-1898.
35. Zulian F, Balzarin M, Falcini F, Martini G, Alessio M, Cimaz R, Cimino L, Zannin ME. Abatacept for severe anti-tumor necrosis factor a refractory juvenile idiopathic arthritis-related uveitis. Arthritis Care Res. 2010;62(6):821-825.
36. Elhai M, Deslandre CJ, Kahan A. Abatacept for refractory juvenile idiopathic arthritis-associated uveitis: two new cases. Comment on the article by zulian et al. Arthritis Care Res (Hoboken) 2011;63(2):307-308.
37. Kenawy N, Cleary G, Mewar D, Beare N, Chandna A, Pearce I. Abatacept: A potential therapy in refractory cases of juvenile idiopathic arthritis-associated uveitis. Graefes Arch Clin Exp Ophthalmol. 2011;249(2):297-300.
38. Sadreddini S, Noshad H, Molaeefard M, Noshad R. Treatment of retinal vasculitis in behcet's disease with rituximab. Mod Rheumatol. 2008;18(3):306-308.
39. Davatchi F, Shams H, Rezaipoor M, Sadeghi-abdollahi B, Shahram F, Nadji A, Chams-Davatchi C, Akhlaghi M, Faezi T, Naderi N. Rituximab in intractable ocular lesions of behcet's disease; randomized single-blind control study (pilot study) Int J Rheum Dis. 2010;13(3):246-252.
40. Heiligenhaus A, Miserocchi E, Heinz C, Gerloni V, Kotaniemi K. Treatment of severe uveitis associated with juvenile idiopathic arthritis with anti-cd20 monoclonal antibody (rituximab). Rheumatology. 2011;50(8):1390-1394.
41. Miserocchi E, Pontikaki I, Modorati G, Bandello F, Meroni PL, Gerloni V. Rituximab for uveitis. Ophthalmology. 2011;118(1):223-224.
42. Miserocchi E, Modorati G. Rituximab for noninfectious uveitis. Dev Ophthalmol. 2012;51:98-109.
43. Liu MM, Tuo J, Chan CC. Republished review: gene therapy for ocular diseases. Postgrad Med J. 2011;87(1029):487-495.
44. Chu C, Barker S, Dick A, Ali R. Gene therapy for noninfectious uveitis. Ocul Immunol Inflamm. 2012;20(6):394-405.
45. Srivastava A, Rajappa M, Kaur J. Uveitis: Mechanisms and recent advances in therapy. Clin Chim Acta. 2010;411(17):1165-1171.
46. Trittibach P, Barker SE, Broderick CA, Natkunarajah M, Duran Y, Robbie SJ, Bainbridge JW, Smith AJ, Sarra GM, Dick A D, Ali RR. Lentiviral-vector- mediated expression of murine il-1 receptor antagonist or il-10 reduces the severity of endotoxin-induced uveitis. Gene Ther. 2008;15(22):1478-1488.
47. Tsai ML, Horng CT, Chen SL, Xiao X, Wang CH, Tsao YP. Suppression of experimental uveitis by a recombinant adeno-associated virus vector encoding interleukin-1 receptor antagonist. Mol Vis. 2009;15:1542-1552.
48. Tian L, Yang P, Lei B, Shao J, Wang C, Xiang Q, Wei L, Peng Z, Kijlstra A. AAV2-mediated subretinal gene transfer of hIFN-a attenuates experimental autoimmune uveoretinitis in mice. PLoS One. 2011;6(5):e19542.
49. Tian L, Lei B, Shao J, Wei L, Kijlstra A, Yang P. AAV2-mediated combined subretinal delivery of IFN-a and IL-4 reduces the severity of experimental autoimmune uveoretinitis. PLoS One. 2012;7(6):e37995.
50. Shao J, Tian L, Lei B, Wei L, Yang Y, Kijlstra A, Yang P. AAV2-mediated subretinal gene transfer of mil-27p28 attenuates experimental autoimmune uveoretinitis in mice. PLoS One. 2012;7(5):e37773.
51. Kim DH, Rossi JJ. Strategies for silencing human disease using rna interference. Nat Rev Genet. 2007;8(3):173-184.
52. Shulyayeva O, Bitko V, Musiyenko A. Inhibition of respiratory viruses by nasally administered sirna. Nat Med. 2005;11(1):50-55.
53. Choi B, Hwang Y, Kwon HJ, Lee ES, Park KS, Bang D, Lee S, Sohn S. Tumor necrosis factor alpha small interfering RNA decreases herpes simplex virus-induced inflammation in a mouse model. J Dermatol Sci. 2008;52(2):87-97.
54. Hou Y, Xing L, Fu S, Zhang X, Liu J, Liu H, Lv B, Cui H. Down-regulation of inducible co-stimulator (ICOS) by intravitreal injection of small interfering rna (siRNA) plasmid suppresses ongoing experimental autoimmune uveoretinitis in rats. Graefes Arch Clin Exp Ophthalmol. 2009;247(6):755-765.
55. Iwata D, Kitamura M, Kitaichi N, Saito Y, Kon S, Namba K, Morimoto J, Ebihara A, Kitamei H, Yoshida K, Ishida S, Ohno S, Uede T, Onoé K, Iwabuchi K. Prevention of experimental autoimmune uveoretinitis by blockade of osteopontin with small interfering RNA. Exp Eye Res. 2010;90(1):41-48.